These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7295079)

  • 1. Modeling of middle molecules in clinical studies.
    Gotch FA; Sargent JA
    Artif Organs; 1981; 4 Suppl():133-6. PubMed ID: 7295079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of hemodialysis on endogenous middle molecules in uremic patients.
    Asaba H; Fürst P; Oulés R; Yahiel V; Zimmerman L; Bergström J
    Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation and excretion of middle molecules.
    Asaba H
    Clin Nephrol; 1983 Mar; 19(3):116-23. PubMed ID: 6839560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bench to bedside view of uremic toxins.
    Vanholder R; Baurmeister U; Brunet P; Cohen G; Glorieux G; Jankowski J;
    J Am Soc Nephrol; 2008 May; 19(5):863-70. PubMed ID: 18287557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal strategies for the removal of middle molecules.
    Winchester JF; Audia PF
    Semin Dial; 2006; 19(2):110-4. PubMed ID: 16551287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of clinical implications of middle molecules and their kinetics in uremia.
    Funck-Brentano JL; Man NK
    Artif Organs; 1981; 4 Suppl():125-32. PubMed ID: 7295078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing transporters to clear uremic toxins.
    Moe OW
    J Am Soc Nephrol; 2009 Dec; 20(12):2483-4. PubMed ID: 19926890
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical and clinical evidence for uremic toxicity.
    Bouré T; Vanholder R
    Artif Organs; 2004 Mar; 28(3):248-53. PubMed ID: 15046622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The analysis of concentration dependence of uremic lesions in clinical studies.
    Sargent JA; Gotch FA
    Kidney Int Suppl; 1975 Jan; (2):35-44. PubMed ID: 1057691
    [No Abstract]   [Full Text] [Related]  

  • 11. Uremic toxins.
    Vanholder R
    Adv Nephrol Necker Hosp; 1997; 26():143-63. PubMed ID: 8922131
    [No Abstract]   [Full Text] [Related]  

  • 12. [Uremic toxins].
    Vanholder R
    Nephrologie; 2003; 24(7):373-6. PubMed ID: 14650749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chick embryo back skin organ and fibroblast cultures. Extracellular matrix changes induced by dialysate fluid and uraemic toxins in relation to proliferation and differentiation processes.
    Stabellini G; Calastrini C; Pezzetti F; DeMattei M; Dellavia C; Moscheni C; Pellati A; Bedani PL; Vertemati M; Bodo-Lumare M
    Pathology; 2003 Jun; 35(3):231-9. PubMed ID: 14506968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Middle molecules--a marker of endogenous intoxication (a review of the literature)].
    Parfenkova GA; Cherniad'eva IF; Sitina VK
    Vrach Delo; 1987 Apr; (4):72-7. PubMed ID: 3303687
    [No Abstract]   [Full Text] [Related]  

  • 16. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients.
    Bammens B; Evenepoel P; Verbeke K; Vanrenterghem Y
    Am J Kidney Dis; 2005 Sep; 46(3):512-9. PubMed ID: 16129214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Middle molecules and unanswered questions.
    Klinkmann H
    Artif Organs; 1981; 4 Suppl():1-2. PubMed ID: 7295074
    [No Abstract]   [Full Text] [Related]  

  • 18. Genesis of the uraemic syndrome: role of uraemic toxins.
    Hörl WH
    Wien Klin Wochenschr; 1998 Aug; 110(15):511-20. PubMed ID: 9782569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration.
    Leypoldt JK
    Semin Dial; 2005; 18(5):401-8. PubMed ID: 16191181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.